David Young of Processa (NASDAQ: PCSA) buys 1,706 shares at $2.69

Q: How many Processa Pharmaceuticals (PCSA) shares does David Young now hold directly?

After the reported transaction, David Young directly holds 13,813 shares of Processa Pharmaceuticals common stock. This direct position reflects his holdings following the 1,706-share open-market purchase disclosed for April 30, 2026 in the Form 4.

Q: At what price did David Young buy PCSA shares in this Form 4 filing?

David Young’s open-market purchase was executed at $2.69 per share . He acquired 1,706 shares of Processa Pharmaceuticals common stock at this price on April 30, 2026 , as reported in the insider trading disclosure.

Q: What indirect PCSA shareholdings are associated with David Young?

The filing lists indirect ownership of Processa shares for David Young: 742 shares held by CorLyst, LLC, 432 shares held by family entities, and 1,242 shares held by the Young-Plaisance Revocable Trust as of April 30, 2026 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Processa Pharmaceuticals director and executive David Young reported buying additional common stock. On April 30, 2026, he made an open-market purchase of 1,706 shares at $2.69 per share, bringing his direct holdings to 13,813 shares. He also reports indirect ownership of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust.

Insider Trade Summary

Net Buyer: 1,706 shares ($4,589)

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 1,706 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,706	$2.69	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 13,813 shares (Direct, null); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust)

Footnotes (1)

Key Figures

Open-market purchase: 1,706 shares at $2.69 Direct holdings after transaction: 13,813 shares Indirect holdings via CorLyst, LLC: 742 shares +2 more

5 metrics

Open-market purchase 1,706 shares at $2.69 Common Stock on April 30, 2026

Direct holdings after transaction 13,813 shares Common Stock held directly by David Young

Indirect holdings via CorLyst, LLC 742 shares Common Stock held indirectly

Indirect holdings via family entities 432 shares Common Stock held indirectly

Indirect holdings via revocable trust 1,242 shares Common Stock held by Young-Plaisance Revocable Trust

Key Terms

open-market purchase, indirect ownership, Common Stock, net-buy

4 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"ownership_type: "indirect" with nature_of_ownership by entities"

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

net-buy financial

"transactionSummary shows netBuySellDirection "net-buy""

Form 4 Insider Transactions: What Each Field Means →

05/01/2026 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last)

(First)

(Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH

FLORIDA

32960

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/30/2026		P		1,706	A	$2.69	13,813	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PCSA executive David Young report?

David Young reported an open-market purchase of Processa Pharmaceuticals common stock. He bought 1,706 shares at $2.69 per share on April 30, 2026, increasing his direct ownership to 13,813 shares according to the Form 4 filing.

How many Processa Pharmaceuticals (PCSA) shares does David Young now hold directly?

After the reported transaction, David Young directly holds 13,813 shares of Processa Pharmaceuticals common stock. This direct position reflects his holdings following the 1,706-share open-market purchase disclosed for April 30, 2026 in the Form 4.

At what price did David Young buy PCSA shares in this Form 4 filing?

David Young’s open-market purchase was executed at $2.69 per share. He acquired 1,706 shares of Processa Pharmaceuticals common stock at this price on April 30, 2026, as reported in the insider trading disclosure.

What indirect PCSA shareholdings are associated with David Young?

The filing lists indirect ownership of Processa shares for David Young: 742 shares held by CorLyst, LLC, 432 shares held by family entities, and 1,242 shares held by the Young-Plaisance Revocable Trust as of April 30, 2026.

Does the Form 4 for PCSA show any insider sales by David Young?

No sales are shown in this Form 4. The transaction summary reflects one open-market purchase of 1,706 shares and no reported sales, resulting in a net-buy position for the period covered by the filing.